Goldman Sachs is betting heavily on Johnson & Johnson's Icotyde

Goldman Sachs is betting heavily on Johnson & Johnson's Icotyde  marketscreener.com

Summary aggregated from marketscreener.com's public RSS feed. The full reporting belongs to marketscreener.com — please read it on their site.